InvestorsHub Logo
Followers 122
Posts 28155
Boards Moderated 2
Alias Born 10/04/2004

Re: researcher59 post# 111848

Monday, 03/25/2024 11:05:17 AM

Monday, March 25, 2024 11:05:17 AM

Post# of 112576
R59- GERN, thanks

Appreciate your view. I personally believe that Imetelstat will do better than most think. Most importantly, GERNs Imetelstat treats ringed(25%) and un ringed(75%) sideroblasts cell types in low risk MDS equally effecitvely, where as Bristol Myers Reblozyl treats only ringed sideroblasts effectively. There is an article off Google that states this should be an egde for GERN. So maybe, even though Reblozyl has FDA first line status, GERN will definitely be recognized as a major alternative. I mean GERN and Bristol Myers will be sharing an approximate $5B+/year worldwide market by 2030. I don't see how GERN won't eventually get at least $1B/year of that, which would make the stock worth at least $10 IMO.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.